Registration Strip Icon for monitor Monitora più quotazioni in tempo reale dalle principali borse, come Borsa Italiana, NASDAQ, NYSE, AMEX, Bovespa e altro ancora.

CRDF

Cardiff Oncology (CRDF)

Cardiff Oncology Inc
Da:
Ordina per:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:CRDF
DataOraFonteTitoloSimboloCompagnia
13/03/202521:06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CRDFCardiff Oncology Inc
08/03/202513:33PR Newswire (Canada)Why the Global Cancer Market Could Surpass $900 Billion--And the Stocks Leading the ChargeNASDAQ:CRDFCardiff Oncology Inc
27/02/202522:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CRDFCardiff Oncology Inc
27/02/202522:11Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:CRDFCardiff Oncology Inc
27/02/202522:05GlobeNewswire Inc.Cardiff Oncology Reports Fourth Quarter and Full Year 2024 Results and Provides Business UpdateNASDAQ:CRDFCardiff Oncology Inc
27/02/202522:00Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:CRDFCardiff Oncology Inc
24/02/202522:05GlobeNewswire Inc.Cardiff Oncology to Present at Upcoming Investor ConferencesNASDAQ:CRDFCardiff Oncology Inc
20/02/202522:05GlobeNewswire Inc.Cardiff Oncology to Report Fourth Quarter 2024 Results and Provide Business UpdateNASDAQ:CRDFCardiff Oncology Inc
17/12/202422:06Edgar (US Regulatory)Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:CRDFCardiff Oncology Inc
10/12/202413:20GlobeNewswire Inc.Cardiff Oncology Prices Oversubscribed $40 Million Underwritten Registered Direct OfferingNASDAQ:CRDFCardiff Oncology Inc
10/12/202412:00GlobeNewswire Inc.Cardiff Oncology Announces Positive Initial Data from First-line RAS-mutated mCRC Clinical TrialNASDAQ:CRDFCardiff Oncology Inc
19/11/202414:00GlobeNewswire Inc.Cardiff Oncology Announces New Patent with Claims for the Use of Onvansertib in Treating KRAS mutated mCRCNASDAQ:CRDFCardiff Oncology Inc
07/11/202422:05GlobeNewswire Inc.Cardiff Oncology Reports Third Quarter 2024 Results and Provides Business UpdateNASDAQ:CRDFCardiff Oncology Inc
07/11/202422:00Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CRDFCardiff Oncology Inc
30/10/202421:30GlobeNewswire Inc.Cardiff Oncology Announces Journal of Clinical Oncology Publication of Data from Phase 2 Trial in Second-line KRAS Mutant mCRCNASDAQ:CRDFCardiff Oncology Inc
24/10/202420:02Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:CRDFCardiff Oncology Inc
08/08/202422:05GlobeNewswire Inc.Cardiff Oncology Reports Second Quarter 2024 Results and Provides Business UpdateNASDAQ:CRDFCardiff Oncology Inc
01/08/202422:05GlobeNewswire Inc.Cardiff Oncology to Report Second Quarter 2024 Results and Provide Business UpdateNASDAQ:CRDFCardiff Oncology Inc
17/06/202412:10Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:CRDFCardiff Oncology Inc
29/05/202422:05GlobeNewswire Inc.Cardiff Oncology to Present at the Jefferies Healthcare ConferenceNASDAQ:CRDFCardiff Oncology Inc
13/05/202422:05GlobeNewswire Inc.Cardiff Oncology to Present at Upcoming Investor Conferences in MayNASDAQ:CRDFCardiff Oncology Inc
02/05/202422:05GlobeNewswire Inc.Cardiff Oncology Reports First Quarter 2024 Results and Provides Business UpdateNASDAQ:CRDFCardiff Oncology Inc
25/04/202422:05GlobeNewswire Inc.Cardiff Oncology to Report First Quarter 2024 Results and Provide Business UpdateNASDAQ:CRDFCardiff Oncology Inc
08/04/202422:05GlobeNewswire Inc.Cardiff Oncology Presents Novel Preclinical Data at AACR Annual Meeting 2024 that Supports Ongoing First-line RAS-mutated mCRC Clinical StudyNASDAQ:CRDFCardiff Oncology Inc
06/03/202422:05GlobeNewswire Inc.Cardiff Oncology Announces Upcoming Presentations at the AACR Annual Meeting 2024NASDAQ:CRDFCardiff Oncology Inc
29/02/202422:07GlobeNewswire Inc.Cardiff Oncology Reports Fourth Quarter and Full Year 2023 Results and Provides Business UpdateNASDAQ:CRDFCardiff Oncology Inc
29/02/202422:06GlobeNewswire Inc.Cardiff Oncology Provides Clinical Update on Phase 2 Randomized Second-line ONSEMBLE Trial in Patients with RAS-mutated mCRCNASDAQ:CRDFCardiff Oncology Inc
29/02/202422:05GlobeNewswire Inc.Cardiff Oncology Announces First Patient Dosed in Randomized First-line RAS-mutated Metastatic Colorectal Cancer Trial (CRDF-004)NASDAQ:CRDFCardiff Oncology Inc
26/02/202414:00GlobeNewswire Inc.Cardiff Oncology to Present at the Cowen 44th Annual Health Care ConferenceNASDAQ:CRDFCardiff Oncology Inc
22/02/202414:00GlobeNewswire Inc.Cardiff Oncology to Report Fourth Quarter and Full Year 2023 Results and Provide Business UpdateNASDAQ:CRDFCardiff Oncology Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:CRDF